Efficacy and safety of nivolumab with ipilimumab for recurrent malignant pleural mesothelioma after primary surgical intervention
Efficacy and safety of nivolumab with ipilimumab for recurrent malignant pleural mesothelioma after primary surgical intervention
复制标题
纳武单抗联合伊匹单抗治疗初次手术干预后复发性恶性胸膜间皮瘤的疗效和安全性
DOI：
10.1007/s10147-023-02292-3
复制
发表时间：
2023
影响因子：
3.3
通讯作者：
Hasegawa Seiki
中科院分区：
文献类型：
--
作者：
Nakamura Akifumi;Hashimoto Masaki;Kondo Nobuyuki;Matsumoto Seiji;Kuroda Ayumi;Minami Toshiyuki;Kitajima Kazuhiro;Kuribayashi Kozo;Kijima Takashi;Hasegawa Seiki
复发性恶性胸膜间皮瘤（MPM）的治疗仍然具有挑战性。我们的研究检查了nivolumab与ipilimumab治疗复发性MPM后主要治愈意图surgery.MethodsTreatment的疗效，耐受性和安全性包括360 mg nivolumab每3周和1 mg/kg ipilimumab每6周，均静脉内给药。均因疾病进展或严重不良事件（AE）而停药。评价了其他治疗后数据，包括客观缓解率（ORR）、疾病控制率（DCR）、治疗后生存期、无进展生存期（PFS）和AE。使用改良的实体瘤疗效评价标准（RECIST 1.1）评估肿瘤缓解。使用Kaplan-Meier图估计生存分析。使用美国国家癌症研究所通用术语标准进行可行性分析AE版本5.0。结果41例患者接受nivolumab与ipilimumab治疗原发性治愈性手术后复发性MPM（中位随访时间为10.4个月;中位治疗时间为5.1个月）。总体而言，18例患者表现出部分缓解，13例表现出稳定的疾病，10例记录了疾病进展。ORR和DCR分别为43.9%和75.6%。治疗后12个月生存率和PFS率分别为74.2%和40.0%（未计算中位生存期;中位PFS为7.3个月）。此外，29例患者（70.7%）报告了47起AE，包括14例患者（34.1%）报告的3-4级AE。2例患者出现4级肝胆系统疾病，1例患者出现4级中性粒细胞减少。结论纳武单抗联合伊匹单抗治疗MPM术后复发患者可能具有临床疗效，但可能经常出现严重不良事件。
BackgroundTreatment of recurrent malignant pleural mesothelioma (MPM) remains challenging. Our study examined the efficacy, tolerability, and safety of nivolumab with ipilimumab treatment for recurrent MPM after primary curative-intent surgery.MethodsTreatment comprised 360 mg nivolumab every 3 weeks and 1 mg/kg of ipilimumab every 6 weeks, both administered intravenously. Both were discontinued for progressive disease or serious adverse events (AEs). Additional post-treatment data were evaluated, including objective response rate (ORR), disease control rate (DCR), post-treatment survival, progression-free survival (PFS), and AEs. Tumor response was assessed using the modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Survival analysis was estimated using a Kaplan–Meier plot. Feasibility analysis was performed using the National Cancer Institute Common Terminology Criteria for AEs version 5.0.ResultsForty-one patients received nivolumab with ipilimumab for recurrent MPM after primary curative-intent surgery (median follow-up, 10.4 months; median treatment, 5.1 months). Overall, 18 patients exhibited partial response, 13 exhibited stable disease, and 10 had documented progressive disease. ORR and DCR were 43.9 and 75.6%, respectively. The 12-month post-treatment survival rate and PFS rate were 74.2 and 40.0%, respectively (median survival, not calculated; median PFS, 7.3 months). Further, 47 AEs were reported in 29 patients (70.7%), including grade 3–4 AEs in 14 patients (34.1%). Grade 4 hepatobiliary disorders were observed in 2 patients and grade 4 neutropenia was observed in 1.ConclusionNivolumab with ipilimumab treatment in patients with recurrent MPM after primary surgical treatment may be clinically efficacious, although serious AEs may be frequently observed.
登录
查看更多内容
恶性胸膜间皮瘤新辅助化疗继之以胸膜切除术/去皮质术 10 天后发生气漏的并发症和预测因素
影响因子：
3.7
作者：
A. Nakamura;N. Kondo;T. Nakamichi;M. Hashimoto;T. Takuwa;S. Matsumoto;K. Kuribayashi;T. Kijima;S. Hasegawa
通讯作者：
S. Hasegawa
DOI：
10.1053/j.semtcvs.2021.02.003
发表时间：
2021-01-01
影响因子：
2.5
作者：
Nakamura, Akifumi;Hashimoto, Masaki;Hasegawa, Seiki
通讯作者：
Hasegawa, Seiki
纳武单抗联合伊匹单抗治疗恶性胸膜间皮瘤
影响因子：
3.3
作者：
Camille Travert;P. Tomasini;L. Greillier
通讯作者：
L. Greillier
无明显肿瘤或胸膜增厚的早期恶性胸膜间皮瘤的放射学临床病理特征
影响因子：
3.3
作者：
Nakamura Akifumi;Hashimoto Masaki;Kodama Hiroshi;Yuki Michiko;Kondo Nobuyuki;Yamakado Koichiro;Tsujimura Tohru;Kijima Takashi;Hasegawa Seiki
通讯作者：
Hasegawa Seiki
影响因子：
11.5
作者：
Okada, Morihito;Kijima, Takashi;Ohe, Yuichiro
通讯作者：
Ohe, Yuichiro